Back to Library
ID: VLADONIX STATUS: ACTIVE

Vladonix

Research Only

Also known as: Thymus cytamin, Thymic peptide supplement, A-19 thymus peptides

A cytamin-class peptide supplement derived from thymus tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for immune support. Contains peptide complexes rather than defined sequences. No Western clinical validation.

Low Evidence 8 Sources

Research Statistics

Total Sources
8
Human Studies
1
Preclinical
6
Evidence Rating Low Evidence
Research Depth 2/5
Global Coverage 1/5
Mechanism Plausibility 2/5
Overall Score
2 /5

Russian bioregulator (Khavinson lab); thymus-targeted peptide. Some observational studies in elderly subjects from Russian institutes. No independent Western clinical trials. Thymic bioregulation mechanism proposed but lacks Western validation.

Last reviewed February 2026 How we rate →
!
Evidence Level
low
Not approved for human use by any regulatory agency
Limited human clinical trial data
Consult a healthcare provider before use
Not FDA Approved WADA Prohibited

Research Dossier

01 / 5

Overview

What is Vladonix and what does the research say?

Identity
Also Known As
Thymus cytamin • Thymic peptide supplement • A-19 thymus peptides

Mechanism of Action

Vladonix is a cytamin-class supplement containing peptide complexes derived from thymus tissue.

Cytamin Classification

Cytamins are oral peptide supplements in the Russian bioregulator framework, distinct from injectable bioregulators:

  • Derived from animal tissue extracts
  • Contain multiple peptide fractions
  • Marketed as dietary supplements
  • Not single defined compounds

Proposed Mechanisms

  1. Thymic Support - Claimed to support T-cell maturation via peptide signaling
  2. Immune Modulation - Proposed effects on immune cell function
  3. Age-Related Decline - Marketed to address thymic involution

Important Limitations

  • NOT a defined single peptide - contains complex mixture
  • No Western clinical validation
  • Oral bioavailability of peptides generally very low
  • No randomized controlled trials
  • Not approved by any Western regulatory agency

Evidence-Chained Benefits

Evidence-Chained Benefits

Research findings linked to mechanisms and clinical outcomes

Mechanism Thymic peptide complex supporting T-cell development
Emerging 3 direct studies
Benefit may support immune system function
Evidence Level
Very Low
1 Human
2 Animal
1 In Vitro
Mechanism Confidence
Established
Supported
Emerging
Evidence Level
High
Moderate
Low
Very Low

Peptide Interactions

Known and theoretical interactions when combining Vladonix with other peptides. Based on published research and mechanistic considerations.

Synergistic
Compatible
Caution
Avoid

Both target thymus function - Thymalin is injectable extract, Vladonix is oral cytamin supplement. May have overlapping mechanisms.

Vilon

Compatible
Compatible

Both target thymic function - Vilon is synthetic dipeptide, Vladonix is tissue-derived complex.

Both target immune function but different origins - Ta1 is defined 28-AA peptide with FDA orphan status, Vladonix is Russian cytamin supplement.

Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.

References

8 Sources
1 Human
6 Preclinical

Key Studies Cited

Full reference list available on request. All citations link to PubMed for verification.

Methodology Note

This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.

For complete methodology details, see our Methodology page.

Important Disclaimer

This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.

Get Research Alerts

New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.

No spam. Unsubscribe anytime.

Compare Vladonix

Related Peptides

immune

Alpha-Defensins

HNP-1, HNP-2, HNP-3 +5 more

A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.

#immune
immune

KPV

Lys-Pro-Val, Lysine-Proline-Valine, alpha-MSH(11-13) +1 more

A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.

#immune
immune

Kristagen

EDG, Glu-Asp-Gly, Immune tripeptide

A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.

#immune
immune

Lactoferricin

LFcinB, Lactoferricin B, LfcinB +1 more

An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.

#immune
immune

LL-37

Cathelicidin, hCAP18, Human Cationic Antimicrobial Peptide 18 +3 more

The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.

#immune
immune

Murepavadin

POL7080, RG7929

A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.

#immune

Related Content